Successful Elosulfase Alfa Desensitization Protocol in a Patient With Morquio A Syndrome

Pediatrics. 2022 Feb 1;149(2):e2021052648. doi: 10.1542/peds.2021-052648.

Abstract

Patients with lysosomal storage diseases may require modifications to standard drug desensitization protocols; personalized medicine as well as development of new treatment options are needed.

Publication types

  • Case Reports

MeSH terms

  • Anti-Allergic Agents / therapeutic use
  • Chondroitinsulfatases / administration & dosage*
  • Chondroitinsulfatases / blood
  • Chondroitinsulfatases / immunology*
  • Female
  • Humans
  • Mucopolysaccharidosis IV / blood
  • Mucopolysaccharidosis IV / drug therapy*
  • Mucopolysaccharidosis IV / immunology*
  • Omalizumab / therapeutic use
  • Rhinitis, Allergic / blood
  • Rhinitis, Allergic / drug therapy
  • Rhinitis, Allergic / immunology
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Allergic Agents
  • Omalizumab
  • Chondroitinsulfatases
  • GALNS protein, human